E. Roydon Price, Ph.D.

Dr. Price received his PhD in Biochemistry and Molecular Pharmacology from Harvard University.  He worked as an American Cancer Society postdoctoral fellow and later instructor at the Harvard Medical School in the pediatric oncology department at the Dana Farber Cancer Institute. His work focused on cellular signaling pathways that control development and cancer growth. Dr. Price subsequently joined CombinatoRx Inc. where he led the immunology assay development group and later supported the group’s leads as they progressed through clinical trials. As an independent consultant, Dr. Price works with academic, biotech, pharma, and venture capital clients.  His work ranges from evaluation of new drug in-licensing opportunities, interviews of key opinion leaders, research into preclinical and clinical development paths, and market analysis. In addition, Dr. Price has co-founded two start-up companies. Acylin Therapeutics developed drugs to target acyl transferases for treatment of cancer and metabolic diseases and was funded by Arch Ventures which later sold one of the programs to AbbVie. The second start-up, LQT Therapeutics, focuses on new therapies for LQT syndrome, a rare genetic disease that is a major cause of sudden death in adolescents.